Company: DMAC
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001437749-25-026207
Chunk: 16

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 2
Chunk 16
---
 to external service providers such as contract research organizations; clinical support services; clinical development including clinical site costs; outside nursing services; and laboratory testing. R&D costs also include non-clinical testing; fees paid to our contract manufacturing and development organizations and outside laboratories for development of DM199 and related manufacturing processes; costs for production runs of DM199; consulting resources with specialized expertise related to the execution of our development plan for DM199; and personnel costs, including salaries, benefits, non-cash share-based compensation expense; and other personnel costs. Over the past approximately 10 years, our R&D efforts have been primarily focused on developing DM199. At this time, due to the risks inherent in the clinical development process and the clinical stage of our product development programs, we are unable to estimate with any certainty the costs we will incur in completing the development of DM199 through marketing approval. The process of conducting clinical studies necessary to obtain regulatory approval and manufacturing scale-up to support expanded development and potential future commercialization is costly and time consuming. Any failure by us or delay in completing clinical studies, manufacturing scale-up, or in obtaining regulatory approvals could lead to increased R&D expenses and, in turn, have a material adverse effect on our results of operations.
 
   16

  

General and Administrative Expenses
 
G&A expenses consist primarily of salaries and benefits, including non-cash share-based compensation related to our executive, finance, business development and support functions. G&A expenses also include insurance, including directors’ and officers’ liability coverage, rent and utilities, travel expenses, patent costs, and professional fees, including for auditing, tax and legal services.
Other Income, Net
 
Other income, net consists primarily of interest income earned on marketable securities.
 
Results of Operations
 
Comparison of the Three and Six Month Periods Ended June 30, 2025 and 2024
 
The following table summarizes our unaudited results of operations for the three and six month periods ended June 30, 2025 and 2024 (in thousands):
 

                                                    Three Months Ended                              Six Months Ended             
                                                         June 30,                                       June 30,                 
---------------------------------------------------------------------------------------------------------------------------------
                                      2025                    2024                    2025                   2024                
Research and development expenses         $5,822                    $3,928                $11,478                 $7,604         
General and administrative expenses             2,185                     1,710                 4,673                   3,775    
Other income, net                         $(314           )